Area of research
Infectious Diseases · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, SARS-CoV-2 and COVID-19 Research, T-cell and B-cell Immunology, and Viral Infections and Outbreaks Research.
Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndrome.
<i>In vitro</i> cellular tropism and immunomodulatory response to rVSVΔG-ZEBOV-GP in human cells derived from tissues associated with adverse events.
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.
Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.
Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene signature in low-responder hemodialysis patients.
Machine learning approaches to dissect hybrid and vaccine-induced immunity.
Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.
Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.
Establishment and application of a vesicle extraction method for clinical strains of <i>Pseudomonas aeruginosa</i>
Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach.
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant.
Spike-Specific Memory B Cell Response in Hematopoietic Cell Transplantation Recipients following Multiple mRNA-1273 Vaccinations: A Longitudinal Observational Study.
Analysis of the utility of a rapid vesicle isolation method for clinical strains of <i>Pseudomonas aeruginosa</i>.
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein.
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV.
<i>Salmonella</i> Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort.
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine.
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.
Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts.
Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis.
Characterization of nanoparticles-based vaccines for COVID-19.
Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration.
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2.
A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses.